Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group
October 30, 2023 at 01:00 pm EDT
Share
Quantum Leap Healthcare Collaborative (QLHC) announced the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer. The study is evaluating three investigational endocrine therapy arms: (Z)-endoxifen, a selective estrogen receptor modulator (SERM) in development by Atossa Therapeutics; HAVAH T+Ai?, a proprietary combination of testosterone (T) and anastrozole (Ai) that targets the androgen and estrogen receptor pathways in development by Havah Therapeutics; and ORSERDU® (elacestrant), the only FDA approved oral selective estrogen receptor degrader (oSERD) in development by Stemline Therapeutics Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group. Surgery is the current standard treatment for DCIS even though many patients never progress to breast cancer,
which means that patients are often over-treated with invasive procedures. This new trial, sponsored and
operated by QLHC, offers DCIS patients up to six months of endocrine therapy with the intent to forego surgery
and instead be monitored via long-term active surveillance, if appropriate. A key element in reducing
overtreatment of DCIS is identifying biomarkers that reflect the risk of progression so that those with low-risk
lesions are spared surgery. RECAST DCIS features the assessment of imaging and molecular-based biomarkers in
addition to evaluating new investigational agents in this setting. The study is open to enrollment with each
investigational agent arm expected to enroll up to 110 patients.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing medicines in areas of unmet medical need in oncology with a focus on breast cancer. The Companyâs lead drug candidate under development is oral (Z)-endoxifen, which the Company is developing in two settings: one to treat breast cancer by reducing tumor cell activity prior to surgery and another to reduce breast tissue density in women. Its programs under development include (Z)-endoxifen Programs, AT-H201, and other programs. (Z)-endoxifen is an active metabolite of tamoxifen, to treat and prevent breast cancer in high-risk women. It is developing a form of (Z)-endoxifen, which is administered orally for the potential treatment of breast cancer and reduction of breast density. AT-H201 is for lung injury caused by cancer treatments. AT-H201 consists of a combination of two drugs to treat other diseases. Its other programs include Immunotherapy/CAR-T Programs, which is in early stage of development.
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group